USC researchers identify tumor suppressor that manages cellular cleaning and recycling proceses

07-02-2008

Findings provide insight into regulation of trafficking pathways

Researchers at the University of Southern California (USC) have identified a specific tumor suppressor that manages membrane traffic routes for cellular cleaning and recycling.

The study will be published in the July issue of the journal Nature Cell Biology, and is now available online.

"Our studies indicate that UVRAG tumor suppressor functionally connects and manages two distinct but converged membrane traffic routes for garbage cleaning and cargo recycling," says Chengyu Liang, M.D., Ph.D., assistant professor of research in the Department of Molecular Microbiology and Immunology at the Keck School of Medicine of USC.

The study identified a novel mechanism of the UVRAG tumor suppressor in regulation of autophagy, a mechanism that enables cells to digest or turn over their own contents for maintaining homeostasis (a balanced, stable condition) and responding to various stresses.

Autophagy is marked by the assembly of specialized vesicles called autophagosomes (the cellular equivalent of garbage bags) that engulf damaged proteins, organelles and invading microbes. The "bagged garbage" is then delivered to lysosomes (the cell's garbage disposal system) through autophagic trafficking that involves autophagosome-lysosome fusion. This fusion disposes of waste with the help of lysosomal enzymes for recycling.

The findings of the study indicate that the tumor suppressor UVRAG not only facilities autophagosome formation, but also facilitates autophagosome maturation by association with the C Vps complex, a cellular machinery that facilitates membrane fusion.

In addition to identifying a novel mechanism of the UVRAG tumor suppressor in autophagy regulation, the study also identified UVRAG as an important effector protein in membrane trafficking and demonstrated the connection between endocytic and autophagic trafficking. The research conducted by Liang and colleagues with Jae U. Jung, Ph.D., professor and chair of the Department of Molecular Microbiology and Immunology at the Keck School of Medicine, suggests a functional connection and coordinated regulation of two distinct but converged membrane trafficking pathways.

"The report provides new insights into understanding some human diseases with compromised autophagic and endosomal trafficking, including cardiomyopathy (a disease of the heart muscle), myopathy (a neuromuscular disease), neuronal ceroid lipofuscinosis (genetic disorders of nerve cells) and Danon Disease )a genetic disorder characterized by heart problems)," Liang says.

The findings warrant further study into whether the UVRAG-mediated trafficking activity contributes to its tumor suppression function, she says.

The study was supported by grants from the U.S. Public Health Service and the Leukemia & Lymphoma Society.

Chengyu Liang, Jong-soo Lee, Kyung-Soo Inn, Michaela U. Gack, Qinglin Li, Esteban A. Roberts, Isabelle Vergne, Vojo Deretic, Pinghui Feng, Chihiro Akazawa and Jae U. Jung. "Beclin 1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking." Nature Cell Biology (July 2008). Doi: 10.1038/ncb1740.

Contact: Meghan Lewit
lewit@usc.edu
323-442-3941
University of Southern California



Related Resources: The Leukemia and Lymphoma Society
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Hana Biosciences' rALLy Clinical Trial of Marqibo Meets Response Criteria to Advance to Full Enrollment
Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective
Acute Myeloid Leukemia (AML)
EpiCept Receives Ceplene(R) Marketing Approval in Europe
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
New leukemia signal could point way to better treatment, Stanford researchers find
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
Phase III Study of Rituxan in Leukemia Meets its Goal
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Chronic Myeloid Leukemia (CML)
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Promyelocytic Blast Crisis of Chronic Myeloid Leukemia during Imatinib Treatment
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Hodgkin Lymphoma
Hodgkin lymphoma -- new characteristics discovered
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
September Is National Leukemia and Lymphoma Awareness Month
Nerve cancer mutations found
Multiple Myeloma
Thalomid® in Induction Improves Progression-free Survival in Elderly with Myeloma
The IMF says journal editorial documents dramatic increase in survival since the 1980s
FDA Approves Vidaza Label Expansion
Bortezomib (Velcade) in Combo Scores For Initial Myeloma Treatment
B-MS boosts biologics pipeline with PDL BioPharma deal
Myelodysplastic Syndrome (MDS)
Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS
FDA Approves Vidaza Label Expansion
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Non-Hodgkin Lymphoma (NHL)
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
September Is National Leukemia and Lymphoma Awareness Month
Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer
Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer